Actively Recruiting
Toripalimab Combined With Definitive CCRT for LACC Patients
Led by Ruijin Hospital · Updated on 2024-04-24
150
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cervical cancer constitutes a significant health burden for women globally. While most patients with early-stage disease can be cured with radical surgery or chemoradiotherapy, patients with high-risk locally advanced disease or with recurrent/metastatic disease have a poor prognosis with standard treatments. Immunotherapies are a rational treatment for this HPV-driven cancer that commonly expresses programmed cell death ligand-1. Toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1, showed promising anti-tumor efficacy in multiple solid tumors. This randomised study is evaluating toripalimab combined with CCRT versus CCRT alone for treatment-naïve LACC.
CONDITIONS
Official Title
Toripalimab Combined With Definitive CCRT for LACC Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged over 18 years
- Newly diagnosed and previously untreated locally advanced squamous cell carcinoma of the uterine cervix
- FIGO 2018 stage IB3 to IVA with no distant metastasis
- ECOG performance status 0-1 without major organ failure
- Voluntary signed informed consent
You will not qualify if you...
- History of immunodeficiency disorders
- Any condition that may increase the risk of treatment as judged by researchers
- Previously received or currently receiving PD-1 antibody treatments or other immunotherapies targeting PD-1/PD-L1
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
Research Team
D
Dan Ou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here